DK2204187T3 - Human influenzavaccine indeholdende fire influenzapeptider - Google Patents

Human influenzavaccine indeholdende fire influenzapeptider

Info

Publication number
DK2204187T3
DK2204187T3 DK10003160.8T DK10003160T DK2204187T3 DK 2204187 T3 DK2204187 T3 DK 2204187T3 DK 10003160 T DK10003160 T DK 10003160T DK 2204187 T3 DK2204187 T3 DK 2204187T3
Authority
DK
Denmark
Prior art keywords
influenza
epitopes
human
epitope
peptides
Prior art date
Application number
DK10003160.8T
Other languages
English (en)
Inventor
Tamar Ben-Yedidia
Raphael Levi
Ruth Arnon
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Application granted granted Critical
Publication of DK2204187T3 publication Critical patent/DK2204187T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DK10003160.8T 1998-11-30 1999-11-28 Human influenzavaccine indeholdende fire influenzapeptider DK2204187T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL12733198A IL127331A0 (en) 1998-11-30 1998-11-30 Peptide-based vaccine for influenza
EP99972929A EP1135159A2 (en) 1998-11-30 1999-11-28 Peptide-based vaccine for influenza

Publications (1)

Publication Number Publication Date
DK2204187T3 true DK2204187T3 (da) 2012-08-20

Family

ID=11072200

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10003160.8T DK2204187T3 (da) 1998-11-30 1999-11-28 Human influenzavaccine indeholdende fire influenzapeptider

Country Status (15)

Country Link
US (3) US6740325B1 (da)
EP (2) EP2204187B1 (da)
JP (1) JP2002531415A (da)
KR (1) KR100703571B1 (da)
AT (1) ATE556719T1 (da)
AU (1) AU766883B2 (da)
BR (1) BR9915811A (da)
CA (1) CA2352454C (da)
DK (1) DK2204187T3 (da)
ES (1) ES2389611T3 (da)
HK (2) HK1040620A1 (da)
IL (3) IL127331A0 (da)
NZ (1) NZ511918A (da)
PT (1) PT2204187E (da)
WO (1) WO2000032228A2 (da)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL127331A0 (en) * 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza
AU2002223398A1 (en) * 2000-08-10 2002-04-08 Tsinghua University A vaccine for influenza virus and its preparation
FI20031536A0 (fi) * 2003-10-20 2003-10-20 Biotie Therapies Oyj Korkean affiniteetin ligandit influenssavirukselle ja menetelmät niiden valmistamiseen
ES2427847T3 (es) 2003-11-04 2013-11-04 The Administrators Of The Tulane Educational Fund Método para prevenir la fusión virus:célula mediante la inhibición de la función de la región de iniciación de la fusión en virus de ARN que tienen proteínas de envuelta fusogénicas de membrana de clase I
GB0716992D0 (en) * 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
AU2006203985A1 (en) * 2005-01-05 2006-07-13 Philadelphia Health And Education Corporation Delivery vehicles, bioactive substances and viral vaccines
AU2006206647C1 (en) 2005-01-19 2011-01-20 Vaxinnate Corporation Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response
FI20060200A0 (fi) * 2005-04-20 2006-02-27 Glykos Finland Oy Menetelmä ihmisen influenssaviruksen sialihahappositoumisspesifisyyden analysoimiseksi
US20090104216A1 (en) * 2005-06-01 2009-04-23 Variation Biotechnologies, Inc. Peptide-Based Influenza Vaccine Formulation
US7871626B2 (en) 2005-08-04 2011-01-18 St. Jude Children's Research Hospital Modified influenza virus for monitoring and improving vaccine efficiency
US7468187B2 (en) * 2005-10-18 2008-12-23 Iowa State University Research Foundation, Inc. Canine influenza virus and related compositions and methods of use
US20090169576A1 (en) * 2005-10-26 2009-07-02 Roberto Crea Influenza combinatorial antigen vaccine
JP2009514536A (ja) * 2005-11-07 2009-04-09 シドニー キンメル キャンサー センター Ｃｄ４０リガンド融合蛋白質ワクチン
CA2632483C (en) 2005-12-06 2014-11-25 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Improved influenza vaccine
US20110027314A1 (en) * 2006-01-27 2011-02-03 Novartis Vaccines And Diagnostics Gmbh & Co. Kg Influenza Vaccines Containing Hemagglutinin and Matrix Proteins
GB0613977D0 (en) 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
EP2476432B1 (en) 2006-03-07 2015-08-19 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof
US20080208486A1 (en) * 2006-03-23 2008-08-28 Jari Natunen Integrated System, Device and Use Thereof
US8222204B2 (en) 2006-05-03 2012-07-17 The Administrators of the Tulane Educational Fund and Autoimmune Technologies, LLC Influenza inhibiting compositions and methods
WO2008002663A2 (en) * 2006-06-28 2008-01-03 The Board Of Trustees Of The Leland Stanford Junior University Immunogenic protein constructs
FI20060946A0 (fi) * 2006-10-26 2006-10-26 Glykos Finland Oy Influenssaviruksen nukleiinihappoja ja peptidejä
EP2139908A4 (en) 2007-03-12 2011-02-16 Antigen Express Inc REMOVAL OF PROTEIN Li INVOLVED IN Li-RNAi CONSTRUCTIONS IN ANTICANCER IMMUNOTHERAPY
WO2009016639A2 (en) 2007-08-02 2009-02-05 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope influenza vaccines
EP2280991B1 (en) 2008-04-18 2016-06-22 VaxInnate Corporation Deletion mutants of flagellin and methods of use
EP2278997B1 (en) 2008-04-21 2016-08-10 Nanobio Corporation Nanoemulsion influenza vaccine
WO2009130618A2 (en) * 2008-04-25 2009-10-29 Institute For Systems Biology Flagellin polypeptide vaccines
CN102084252B (zh) 2008-05-02 2017-03-22 罗切斯特大学 用于流感免疫应答测量的阵列检测器***
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
BR112012000826B1 (pt) 2009-07-06 2022-07-26 Variation Biotechnologies Inc Método para a preparação de vesículas
US9907746B2 (en) 2009-07-06 2018-03-06 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
US9610248B2 (en) 2010-07-06 2017-04-04 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
CN103501811B (zh) 2011-01-13 2016-03-30 变异生物技术公司 用于治疗病毒感染的组合物和方法
CN107296792B (zh) 2011-01-13 2021-07-27 变异生物技术公司 囊泡及由其产生之制剂的制备方法
US9303070B2 (en) 2011-02-22 2016-04-05 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
WO2013006797A1 (en) 2011-07-06 2013-01-10 Nanobio Corporation Human respiratory syncytial virus vaccine
CA2845872C (en) 2011-08-22 2023-03-28 Nanobio Corporation Herpes simplex virus nanoemulsion vaccine
WO2013072768A2 (en) 2011-11-18 2013-05-23 Variation Biotechnologies, Inc. Synthetic derivatives of mpl and uses thereof
CN104302323A (zh) 2012-01-12 2015-01-21 变异生物技术公司 用于治疗病毒感染的组合物和方法
RU2698906C2 (ru) 2012-01-27 2019-09-02 Вэриэйшн Биотекнолоджиз, Инк. Способы и композиции для терапевтических агентов
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
JP2014169278A (ja) 2013-02-05 2014-09-18 Nitto Denko Corp 経皮投与用ワクチン組成物
CA2840941A1 (en) 2013-02-05 2014-08-05 Nitto Denko Corporation Wt1 peptide cancer vaccine composition for transdermal administration
RU2014102945A (ru) 2013-02-05 2015-08-10 Нитто Денко Корпорейшн Вакцинная композиция
JP2014169275A (ja) 2013-02-05 2014-09-18 Nitto Denko Corp 粘膜投与用ワクチン組成物
IN2014CH00395A (da) 2013-02-05 2015-04-03 Nitto Denko Corp
CN103961700A (zh) * 2013-02-05 2014-08-06 日东电工株式会社 粘膜给予用疫苗组合物
KR20140100417A (ko) 2013-02-05 2014-08-14 닛토덴코 가부시키가이샤 경피 투여용 백신 조성물
KR102045029B1 (ko) 2013-02-05 2019-11-14 닛토덴코 가부시키가이샤 점막 투여용 ｗｔ1 펩티드 암 백신 조성물
CN103961307B (zh) 2013-02-05 2019-11-29 日东电工株式会社 经皮给予用wt1肽癌症疫苗组合物
CA2841014A1 (en) 2013-02-05 2014-08-05 Nitto Denko Corporation Tape preparation of wt1 peptide cancer vaccine for transdermal administration
RU2531235C2 (ru) * 2013-02-15 2014-10-20 Общество с ограниченной ответственностью "Универсальные БиоСистемы" (ООО "УБС") Поливалентная вакцина против гриппа на основе гибридного белка
CN103901202B (zh) * 2014-04-04 2015-08-12 中国人民解放军***疾病预防控制中心 基于共有表位甲型流感病毒抗体通用型竞争性elisa检测方法
US10925936B2 (en) 2014-09-03 2021-02-23 Nitto Denko Corporation Vaccine pharmaceutical composition for cell-mediated immunity containing bisphosphonates
US10471141B2 (en) 2014-09-03 2019-11-12 Nitto Denko Corporation Bisphosphonate-containing vaccine pharmaceutical composition for humoral immunity
US11278616B2 (en) 2015-08-06 2022-03-22 Nitto Denko Corporation Immunity induction promoting composition, and vaccine pharmaceutical composition
CN111148528A (zh) 2016-12-28 2020-05-12 英福瓦克思公司 流感疫苗

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
IL101639A0 (en) * 1992-04-17 1992-12-30 Yeda Res & Dev Recombinant influenza vaccines
AU3036597A (en) * 1996-05-21 1997-12-09 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for using peptide complexes/major histocompatibility complex to obtain or purify antigen-specific t cells and to stimulate t cells
IL127331A0 (en) * 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza

Also Published As

Publication number Publication date
EP2204187B1 (en) 2012-05-09
CA2352454C (en) 2013-02-05
NZ511918A (en) 2003-08-29
AU766883B2 (en) 2003-10-23
US20070122424A1 (en) 2007-05-31
US7192595B2 (en) 2007-03-20
HK1040620A1 (zh) 2002-06-21
IL143367A (en) 2006-09-05
AU1406600A (en) 2000-06-19
ATE556719T1 (de) 2012-05-15
KR20010089512A (ko) 2001-10-06
BR9915811A (pt) 2001-08-21
US20050002954A1 (en) 2005-01-06
IL143367A0 (en) 2002-04-21
US7514086B2 (en) 2009-04-07
WO2000032228A3 (en) 2000-10-05
PT2204187E (pt) 2012-08-10
KR100703571B1 (ko) 2007-04-05
US6740325B1 (en) 2004-05-25
WO2000032228A2 (en) 2000-06-08
CA2352454A1 (en) 2000-06-08
HK1145448A1 (en) 2011-04-21
ES2389611T3 (es) 2012-10-29
EP1135159A2 (en) 2001-09-26
EP2204187A1 (en) 2010-07-07
IL127331A0 (en) 1999-09-22
JP2002531415A (ja) 2002-09-24

Similar Documents

Publication Publication Date Title
DK2204187T3 (da) Human influenzavaccine indeholdende fire influenzapeptider
JP2002531415A5 (da)
Liu et al. High epitope density in a single recombinant protein molecule of the extracellular domain of influenza A virus M2 protein significantly enhances protective immunity
Schild et al. Fine specificity of cytotoxic T lymphocytes primed in vivo either with virus or synthetic lipopeptide vaccine or primed in vitro with peptide.
ES2619332T3 (es) Fosfatasa alcalina dirigida al hueso, kits y métodos de uso de la misma
ES2721172T3 (es) Una nueva clase de moléculas terapéuticas a base de proteínas
AR008765A1 (es) Un peptido o un derivado, analogo o variante, funcional del mismo, un peptido recombinante o sintetico del mismo, una secuencia nucleotidica y vectorque la contiene, una celula huesped transformada, un procedimiento para su preparacion, una composicion farmaceutica que lo comprende, un compuesto del
AR038568A1 (es) Anticuerpos anti-a beta y su uso
ATE277633T1 (de) Präparate und verfahren zum auslösen von ctl- immunität
RS51602B (sr) April receptor (bcma) i njegova upotreba
ES2121830T3 (es) Procedimiento para la preparacion a escala industrial de un concentrado de factor de willebrand humano normalizado de pureza muy elevada apropiado para uso terapeutico.
NO880494L (no) Syntetiske nonapeptid- og decapeptidanaloger av lhrh som er anvendelige som lhrh-antagonister.
BRPI0519705A2 (pt) composiÇÕes, proteÍnas de fusço e mÉtodos de estimular uma resposta imune em um indivÍduo
NO990533L (no) GnRH-leukotoksin kimµrer
DE69939327D1 (de) Funktionelle antagonisten von hedgehog-aktivität
ZA936629B (en) Potentiation of immunogenic response
Hackett et al. A synthetic decapeptide of influenza virus hemagglutinin elicits helper T cells with the same fine recognition specificities as occur in response to whole virus.
ES2127294T3 (es) Vacunas del virus de la inmunodeficiencia anti-felino (fiv).
Wabuke-Bunoti et al. Cytolytic T lymphocyte and antibody responses to synthetic peptides of influenza virus hemagglutinin.
ES2171086T3 (es) Uso de proteinas hmg para la preparacion de medicamentos con actividad citotoxica.
DK0707473T3 (da) Orale farmaceutiske præparater omfattende et protein eller et peptid, et antistof og polymerkugler
DE60036692D1 (de) Zusammensetzungen und methoden zur detektion einer trypanosoma cruzi infektion
DE69527708D1 (de) Synthetischer impfstoff zum schutz gegen infektionen mit dem menschlichen immunschwächevirus
ATE208421T1 (de) Stimulierung der immunantwort durch virales protein
Cole et al. T cell recognition of the immunodominant Sendai virus NP324-332/Kb epitope is focused on the center of the peptide.